Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma

Annals of Oncology

Volumn 11, Issue 2, 2000, Pages 201-206

  White, S C ^a   Anderson, H ^a   Jayson, G C ^a   Ashcroft, L ^a   Ranson, M ^a   Thatcher, N ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Cisplatin; Infusional carboplatin; Mesothelioma; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HUMAN; INFUSION PUMP; LETHARGY; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; NAUSEA; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

EID: 0034055754     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008328605413     Document Type: Article

References (31)

1. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 1996; 14: 1007-17.
2. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 1986; 4: 702-9.
3. Bonomi PD, Finkelstein DM, Ruckdeschel JC et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7: 1602-13.
4. Klastersky J, Sculier JP, Lacroix H et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990; 8: 1556-62.
5. Gatzemeier U, Rosell R, Betticher D et al. Randomised pan-European trial comparing paclitaxel carboplatin versus paclitaxel cisplatin in advanced non-small-cell lung cancer. Proc Eur Cancer Con 1999; 35: S246.
6. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409-22.
7. Micetich KC, Barnes D, Erickson LC. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino) (1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diammine-dichloroplatinum(II) on L1210 cells. Cancer Res 1985; 45: 4043-7.
8. Baserga R. The cell cycle. N Engl J Med 1981; 304: 453-9.
9. Posner MR, Ferrari L, Belliveau JF et al. A phase I trial of continuous infusion cisplatin. Cancer 1987; 59: 15-8.
10. Goldberg RM, Jett JR, Therneau TM et al. Bolus versus infusion regimens of etoposide and cisplatin in treatment of non-small-cell lung cancer: A study of the North Central Cancer Treatment group. J Natl Cancer Inst 1990; 82: 1899-903.
11. Lokich J, Anderson N, Bern M et al. Infusional carboplatin. Phase I studies of 5-day and 14-day infusions. Cancer 1991; 68: 68-71.
12. Smit EF, Willemse PH, Sleijfer DT et al. Continuous infusion carboplatin on a 21-day schedule: A phase I and pharmacokinetic study. J Clin Oncol 1991; 9: 100-13.
13. Leyvraz S, Ohnuma T, Lassus M, Holland JF. Phase I study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion. J Clin Oncol 1985; 3: 1385-92.
14. Ruckdeschel JC, Finkelstein DM, Ettinger DS et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986; 4: 14-22.
15. Olver IN, Webster LK, Millward MJ et al. A phase I and pharmacokinetics study of prolonged ambulatory-infusion carboplatin. Cancer Chemother Pharmacol 1995; 37: 79-85.
16. Anderson H, Hopwood P, Prendiville J et al. A randomised study of bolus vs. continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer. Br J Cancer 1993; 67: 1385-90.
17. Eisenhauer EA, Evans WK, Murray N et al. A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study. Invest New Drugs 1988; 6: 327-9.
18. Mbidde EK, Harland SJ, Calvert AH, Smith IE. Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 1986; 18: 284-5.
19. Raghavan D, Gianoutsos P, Bishop J et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990; 8: 151-4.
20. Tsavaris N, Primikirios N, Mylonakis N et al. Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A retrospective study. Anticancer Res 1997; 17: 3799-802.
21. Chatelut E, Canal P, Brunner V et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87: 573-80.
22. Calvert AH, Harland SJ, Newell DR et al. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev 1985; 12 (Suppl A): 51-7.
23. Guillet P, Monjanel S, Nicoara A et al. A Bayesian dosing method for carboplatin given by continuous infusion for 120 hours. Cancer Chemother Pharmacol 1997; 40: 143-9.
24. Lilenbaum RC, Langenberg P, Dickersin K. Single-agent versus combination chemotherapy in patients with advanced non-small-cell lung carcinoma: A meta-analysis of response, toxicity, and survival. Cancer 1998; 82: 116-26.
25. Sandler J, Nemunaitis J, Dehnam C. Phase III study of cisplatin with or without gemcitabine in patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1998; 17: 454a.
26. von Pawel J, von Roemeling R for the International CATAPULT-I Study Group. Survival benefit from Tirazone (tirapazamine) and cisplatin in advanced non-small-cell lung cancer patients: Final results from the international phase III CATAPULT I study. Proc Am Soc Clin Oncol 1998; 17: 454a.
27. Wozniak AJ, Crowley JJ, Balcerzak SP et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 1998; 16: 2459-65.
28. Manegold C, Bergman B, Chemaissani A et al. Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 1997; 8: 525-9.
29. Schaake Koning C, van den Bogaert W, Dalesio O et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung. N Engl J Med 1992; 326: 524-30.
30. Groen HJ, van der Leest AH, de Vries EG et al. Continuous carboplatin infusion during six weeks' radiotherapy in locally inoperable non-small-cell lung cancer: A phase I and pharmacokinetic study. Br J Cancer 1995; 72: 992-7.
31. Clamon G, Herndon J, Cooper R et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 17: 4-11.